乳腺微小钙化灶的外科微创治疗

目的探讨乳腺微小钙化灶的外科微创治疗。方法采用意大利IMS生产的GITTOHI—TECH高频钼靶X线机及其配套的数字化立体定位活检系统,对30例钼靶X片上乳腺有微小钙化病灶、无任何临床体征的患者,在X线定位下穿刺活检,进行病理组织学检查。明确诊断后采取相应的手术方式治疗。结果全部病灶定位准确,病变完全切除并明确诊断。浸润性导管癌3例(10%),导管内癌6例(20%),重度不典型增生2例(6.7%),纤维腺瘤6例(20%),导管内乳头状瘤3例(10%),乳腺增生病10例(33.3%)。无金属导丝折断现象,无感染、切口延迟愈合及气胸等并发症。结论对X线片显示有恶性可能的钙化病灶、而临床未触及肿块者,行乳腺钼靶引导下导丝定位活检,切除乳腺组织少,能确定乳腺微小病变的性质,对早期乳腺癌的诊断有重要价值。     

乳腺X线三维立体定位真空辅助乳腺活检在乳腺X线可疑钙化诊断中的价值北大核心CSCD

目的探讨乳腺X线三维立体定位真空辅助乳腺活检在可疑钙化中的应用价值。方法2016年1月~2018年12月对242例临床不可触及且超声检查阴性,乳腺X线可疑钙化,在乳腺X线三维立体定位下采用EnCor真空辅助乳腺活检系统旋切取活检,利用乳腺X线0°导航位和±15°立体定向确定病灶位置后,从该位置插入旋切刀进行微创旋切取活检。结果242例顺利完成活检,活检病理诊断良性病变205例(非典型病变16例),恶性病变37例(导管原位癌30例,浸润性导管癌7例)。37例恶性病变手术治疗,7例为浸润性导管癌,其中5例钙化完全切除,手术时无肿瘤残留,2例有残余微钙化和残余肿瘤;30例为导管原位癌(ductal carcinoma in situ,DCIS),其中28例钙化病灶完全切除,2例活检术中有肿瘤残留[手术切除标本示导管内癌伴早期浸润,DCIS升级率为6.7%(2/30)]。11例非典型性病变手术治疗,10例术后病理诊断为腺病,1例升级为DCIS,非典型增生升级率9.0%(1/11);5例非典型病变在3年的随访中无可疑发现。结论乳腺X线立体定位下真空辅助乳腺活检可以较好地应用于可疑钙化的微创活检,值得推广。     

X线立体定位真空辅助活检对临床不可触及且超声检查阴性的钼靶乳腺微小钙化的应用价值

目的探讨乳腺X线立体定位真空辅助活检(stereotactic vaccum-assisted breast biopsy,SVAB)对临床不可触及且超声检查阴性的钼靶乳腺微小钙化的应用价值。方法 2011年1月~2013年12月,对278例临床不可触及且超声检查阴性的钼靶乳腺微小钙化行SVAB,BI-RADSⅣ级261例,Ⅴ级17例。病理诊断为乳腺癌进一步手术治疗;轻、中度乳腺导管上皮不典型增生(atypical ductal hyperplasia,ADH)病例采取影像学随访1年以上,重度ADH则进一步手术活检;除ADH外的良性病变结束治疗。结果 SVAB活检成功率为99.3%(276/278)。病理诊断乳腺癌27例(9.7%),包括导管内癌22例,导管内癌微浸润3例,浸润性导管癌2例,22例导管内癌组织学低估率为18.2%(4/22);乳腺ADH 27例(9.7%),其中轻度ADH 18例,中度ADH 4例,重度ADH 5例,未发现组织学低估;除ADH外的良性病变224例(80.6%),包括纤维囊性乳腺病129例,硬化性腺病85例,乳头状瘤10例。BI-RADSⅣ级恶性率5.0%(13/261),Ⅴ级恶性率82.4%(14/17)。结论临床不可触及且超声检查阴性的钼靶下乳腺微小钙化行SVAB可明确诊断乳腺癌和ADH,对ADH未见组织学低估,且不需要全部进一步手术切检,有较高的临床应用价值。     

非肿块型乳腺导管癌数字化乳腺X线摄影表现形式与病理类型的相关性分析

目的探讨非肿块型乳腺导管癌数字化乳腺X线摄影(DR)表现形式与病理类型的相关性。方法回顾性分析经手术、病理证实的非肿块型乳腺导管癌195例,其中导管内癌36例(1组),导管内癌伴微浸润25例(2组),浸润性导管癌58例(3组),浸润性导管癌伴导管内癌76例(4组),对DR表现形式及病灶长径进行对比和统计学处理。结果 DR表现形式与病理类型关系在总体上差异有统计学意义(P0.05),x~2分割检验显示导管内癌与浸润性导管癌组及浸润性导管癌伴导管内癌组差异均有统计学意义(P0.008),后两组之间差异有统计学意义(P0.008),病灶长径与病理类型关系在总体上差异有统计学意义(P0.05),x~2分割显示导管内癌与浸润性导管癌伴导管内癌组差异有统计学意义(P0.008),浸润性导管癌与浸润性导管癌伴导管内癌组差异有统计学意义(P0.008),其他组之间差异无统计学意义(P0.008)。结论导管内癌DR表现形式主要是单纯钙化;以片影伴钙化为表现的,病理类型多是浸润性导管癌伴导管内癌;病灶长径50 mm,浸润性导管癌伴导管内癌的可能性大。     

ATEC活检系统在乳腺钙化灶立体定位活检中的应用

目的探讨ATEC活检系统在可疑乳腺癌钙化灶X线立体定位真空辅助活检(stereotactic vacuum-assisted biopsy,SVAB)中的应用价值。方法 2018年7月～2019年12月198例(215侧乳房)因乳腺钙化灶使用ATEC活检系统行SVAB,回顾性评估该活检系统的有效性、安全性及组织学低估率。结果 215侧乳房均顺利完成活检,病理示良性病变165侧,非典型导管上皮增生19侧,恶性病变31侧(其中导管原位癌25侧,导管原位癌伴局灶浸润性导管癌3侧,浸润性导管癌2侧,浸润性微乳头状癌1侧)。组织学低估率导管原位癌为16.0%(4/25),非典型导管上皮增生为5.3%(1/19)。结论ATEC系统可以较好地应用于中国女性常见可疑钙化灶微创活检,值得推广。     

乳腺钼靶X线三维立体定位系统引导下导丝定位活检的临床应用

目的探讨乳腺钼靶X线三维立体定位系统引导下导丝定位手术活检在临床不能触及肿块的乳腺病变中的价值及可行性。 方法回顾性研究2013年4月至2015年10月间收治的乳腺钼靶X线异常女性患者67例,对临床不能触及的乳腺病灶行导丝定位手术活检及病理检查。 结果67例病灶均一次定位成功,发现乳腺癌17例（25.4%）,癌前病变（导管上皮非典型增生及导管内乳头状瘤）13例（19.4%）,其他良性病变37例（55.2%）。影像表现为微钙化灶的46例病例中乳腺恶性病变共16例（34.8%）,癌前病变8例（17.4%）,其他良性病变22例（47.8%）;非钙化组的21例病例中良性病变20例（95.2%）,恶性病变1例（4.8%）。与影像表现为非钙化组比较,对于临床不能触及的乳腺病灶,乳腺钼靶X线影像表现为微钙化时乳腺癌检出率更高（χ²=5.369,P=0.021）。 结论钼靶X线三维立体定位系统引导下导丝定位活检可以发现容易漏诊的早期乳腺癌及癌前病变,该方法简便、准确,值得推广。     

钼靶联合超声引导双定位法在乳腺微钙化灶活检中的 临床应用研究

目的:探讨钼靶X线与超声联合定位在乳腺微钙化灶活检中的临床应用价值。方法:在钼靶下对微钙化病灶三维定位,插入双钩定位针,到达病灶后固定位置;以超声探查双钩针,找到病灶的位置后,划出皮肤标记线,再插入单钩定位针;在标记线上作3 cm切口,用特制拉钩显露并固定病灶部位的乳腺组织和单钩针,对微钙化病灶区进行旋切;切下的圆柱体标本,放在带刻度的标本台上摄片,验证钙化灶是否已被完全切除,同时确定钙化灶在标本中的三维位置供病理检查。结果:共108例乳腺微钙化病灶分类为BI-RADS 4A的患者采用以上方法。定位时病灶距双钩针距离平均为4.1 mm(小于传统方法),标本平均重量为8.5 g(小于传统方法),病灶全部被一次性精准切除。108例中阳性20例,包括不典型增生7例,导管原位癌7例,导管原位癌伴局灶浸润性癌3例,浸润性导管癌3例;阴性病例88例。微钙化灶部位及形态与乳腺癌检出无明显关系(均P0.05)。结论:钼靶X线与超声联合定位对病灶定位准确、手术方法合理、切除标本小,并能提供病灶在标本中的精确位置进行病理检查;良性者乳房外形完全没有改变。     

超声检测乳腺癌微小钙化的影响因素及与钼靶X线摄影的对比

【摘要】〓目的〓比较超声与钼靶X线摄影检测乳腺癌微小钙化的一致性,探讨影响超声检测乳腺癌微小钙化的影响因素。方法〓87例乳腺癌行超声及钼靶X线摄影检查,分析二者的乳腺病灶及微小钙化的特点,比较二者检测的一致性,分析超声检测微小钙化的影响因素。结果〓超声对病灶的显示率及诊断恶性的准确率均高于钼靶(χ2=9.911,P=0.002)。二者在微小钙化的检出方面无统计学差异(P>0.05),具有较高的一致性(k=0.652)。以钼靶显示微小钙化作为标准,超声检测微小钙化的敏感度为82.1%,特异度为83.3%,假阳性率16.7%,假阴性率为17.9%。钼靶上微小钙化的大小及密集程度影响其超声检测(P<0.05)。结论〓超声较钼靶X线摄影能更敏感地检测及诊断乳腺恶性病变;超声能有效地检测乳腺癌微小钙化,但易受微小钙化的大小及密集程度的影响。     

原发性乳腺淋巴瘤的影像学表现与病理学特征

目的分析原发性乳腺淋巴瘤的超声、钼靶X线、CT的影像学表现及组织病理学特征。方法回顾性分析40例(47个病灶)原发性乳腺淋巴瘤的临床资料、超声、钼靶X线、CT表现及病理特征。结果 40例中超声检出47个肿块,33个(33/47,70.21%)呈椭圆形或圆形,40个(40/47,85.11%)边界清晰,35个(35/47,74.47%)表现为低回声,31个(31/47,65.96%)后方回声增强,26个(26/47,55.32%)有较丰富血流信号。对21例行钼靶X线检查,于18例中发现21个病灶,11个(11/21,52.38%)边界清楚,14个(14/21,66.67%)形态规则,18个(18/21,85.71%)呈高密度。对7例行CT检查,共检出8个病灶,6个(6/8,75.00%)病灶为等增强或略高增强的规则肿块;所有病灶均无钙化、毛刺征。结论原发性乳腺淋巴瘤影像学表现有一定特点,但仍缺乏特异性,确诊仍要依靠组织病理学及免疫组化。     

乳腺数字化摄影中微钙化的临床分析

目的分析数字化摄影中微钙化相关乳腺癌病人的临床及影像学资料,探讨其危险因素,从而指导临床对微钙化病人的早期诊断与治疗。方法数字化摄影发现微钙化为表现的病人447例,均经活检或手术病理证实,对其临床及影像学资料进行分析,比较其在良恶性病变中的差异。结果 447例病人共检出乳腺癌93例(20.8%),其中导管内癌52例(11.6%),导管内癌伴浸润29例(6.5%),浸润性癌12例(4.7%);良性病例354例(79.2%),其中增生病腺病297例(66.4%),纤维腺瘤37例(8.3%),导管瘤10例(2.2%),导管扩张4例(0.9%),间质慢性炎4例(0.9%),硬化性腺病2例(0.4%)。恶性病变钙化与良性病变钙化在患侧位置、钙化的分布、钙化的形态、钙化的密集度、钙化的范围、乳腺影像报告和数据系统(breast imaging reporting date system,BI-RADS)分类比较差异有统计学意义(P0.05),其中在钙化分布、钙化形态、BI-RADS分类方面差异有统计学意义(P0.05)。结论微钙化的分布(团簇状及线样/段样)、形态(细小多形性及细线/细线分枝状)、BI-RADS分类(4类及5类)等是影响病理结果的重要因素。     

Determination of the presence and extent of pure ductal carcinoma in situ by mammography and magnetic resonance imaging

The purpose of this study was to compare the ability of magnetic resonance imaging (MRI) and mammography to determine the presence and extent of ductal carcinoma in situ (DCIS). Retrospective review of medical records of women who underwent MRI and mammographic examination during a 23-month period revealed 39 sites of pure DCIS in 33 breasts of 32 women. No invasive or microinvasive tumor was found. Women ranged in age from 34 to 79 years (mean age 53 years). In these 33 breasts, both MRI and mammography were done before surgery. Reports and images of mammography and MRI were reviewed to determine if each study was positive for the presence of single or multiple sites of DCIS and the imaging patterns associated with these sites. Of 33 breasts involved, DCIS was discovered by MRI alone in 21 (64%), by both MRI and mammography in 8 (24%), and by mammography alone in 1 (3%); in 3 breasts (9%), DCIS was found at mastectomy without findings on mammography or MRI. MRI had significantly higher sensitivity than mammography for DCIS detection (29/33=88% versus 9/33=27%, p<0.00001). Multiple sites of disease were present in five breasts; these were better demonstrated with MRI in three, mammography in one, and equally by both in one. The predominant enhancement pattern of DCIS on MRI was linear/ductal in 18 of 29 breasts (62%); mammography found calcifications associated with DCIS in 8 of 9 (89%). The nuclear grade of DCIS found with MRI and mammography was similar; size of lesions was larger on MRI; breast density did not impact results. In this study, MRI was significantly more sensitive than mammography in DCIS detection. In women with known or suspected DCIS, MRI may have an important role to play in assessing the extent of disease in the breast.     

乳腺超声及X线检查在鉴别乳腺导管原位癌是否伴微浸润中的价值

目的　比较导管原位癌（DCIS）及导管原位癌伴微浸润（DCISM）超声及X线特征的差异。方法　经手术病理诊断为DCIS和DCISM的病例共147例（DCIS94例,DCISM53例）。超声上,病变分为肿块及非肿块。X线上,病变分为单纯钙化、肿块、局灶不对称或结构扭曲。统计分析采用χ2检验,Fisher确切概率法及多因素logistic回归分析。结果　单因素及多因素分析结果显示,超声上病变内可见钙化及血流提示DCISM可能（P=0.038,P=0.025）。此外,X线上钙化范围越大,DCISM可能性越高（P=0.002）。结论　与DCIS相比,超声上病变内可见钙化及血流、X线上钙化分布范围较大与DCISM相关。     

Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study

Although magnetic resonance imaging (MRI) is much more sensitive than mammography for detecting early invasive breast cancer, in many high-risk screening studies MRI was less sensitive than mammography for detecting ductal carcinoma in situ (DCIS). We reviewed our experience detecting DCIS in our single center study of annual MRI, mammography, ultrasound and clinical breast examination (CBE) for screening very high-risk women. All cases of DCIS±microinvasion and invasive cancer were compared in two time frames: before (period A) and after (period B) July 2001-when we acquired expertise in the detection of DCIS with MRI-with respect to patient demographics, method of detection, and rates of detection of invasive cancer and DCIS. In period A there were 15 cases (3.1% of 486 screens) in 223 women, of which 2 (13%) were DCIS-one with microinvasion-neither detected by MRI. In period B there were 29 cases (3.3% of 877 screens) in 391 women, of which 10 (34%) were DCIS±microinvasion (p=0.04), all 10 detected by MRI but only one by mammography. No DCIS cases were detected by ultrasound or CBE. Specificity was lower in period B than in period A but acceptable. The ability to detect DCIS with screening MRI improves significantly with experience. MRI-guided biopsy capability is essential for a high-risk screening program. In experienced centers the increased sensitivity of MRI relative to mammography is at least as high for DCIS as it is for invasive breast cancer.     

数字化乳腺摄影联合超声与MRI对乳腺良、恶性疾病诊断的对照观察

目的评价数字化乳腺摄影联合超声与MRI在乳腺良恶性疾病诊断中的意义及临床应用价值。方法对105例乳腺疾病患者的数字化乳腺摄影联合超声诊断结果与MRI诊断结果进行回顾性分析。结果 105例患者共110个病灶,其中恶性62个,良性48个。所有病灶均被病理证实。数字化乳腺摄影联合超声对乳腺恶性病变的诊断敏感度、特异度分别为90.32%（56/62）、91.67%（44/48）;MRI对乳腺恶性病变的诊断敏感度、特异度分别为91.94%（57/62）、87.50%（42/48）。结论数字化乳腺摄影联合超声检查诊断准确性高,适用于乳腺疾病的常规检查;MRI空间分辨力及组织分辨力高,适用于前二者检查难以定性的病变及乳腺癌的术前评估。     

乳腺导管内癌:附123例(125侧)报告

目的 加深对导管内癌(DCIS)的认识,以提高其诊断率和治疗效果.方法 回顾性分析中国医科大学附属第一医院普通外科收治的123例DCIS患者的临床资料.包括发病年龄、临床表现、体检特征、超声和钼靶检查、病理特点、免疫组织化学检查和手术方式.结果 (1)该组发病的平均年龄为(47.7±9.3)岁.(2)体检特点以乳腺肿块79例,乳头溢液19例,乳房疼痛伴腺体增厚30例等为主要表现.(3)超声、钼靶45例,可能为恶性者分别为27例(60%),30例(66.7%),方法准确率差异无统计学意义.综合2种方法后,诊断可能恶性者37例(82.2%).(4)65例超声表现为实质性肿见块43例(66%);血流信号41例(63%);可见导管扩张52例(80%)和导管内点状强光团33例(50.7%).(5)52例钼靶摄影主要表现有泥沙样钙化,肿物伴簇状钙化,腺体局限性致密和乳腺肿物.(6)免疫组织化学检查包括雌激素受体(ER),孕激素受体(PR),p53和c-erbB-2.DCIS与DCISMI的阳性表达率差异均无统计学意义.(7)行乳腺癌标准根治术6例(其中3例为DCIS-MI).共行乳腺癌改良根治术86例,包括59例DCIS,27例DCIS-MI.DCIS伴有淋巴结转移者2例,DCIS-MI有淋巴结转移者5例.结论 乳腺超声检查和钼靶摄像联合诊断可提高DCIS的诊断率.     

乳腺导管原位癌的MRI特点分析

目的:分析乳腺导管原位癌的影像学表现及MRI的诊断价值,以进一步提高对乳腺导管原位癌的影像学认识。材料和方法:回顾性分析18例经病理证实为乳腺导管原位癌病人的临床资料,研究其乳腺磁共振图像的形态学特点、动态增强方式及扩散加权成像特点。结果:18例导管原位癌的形态学表现及增强方式大体可分为两类。一类是非肿块型13例(72.2%),包括不规则片状6例和段状改变7例,其时间-信号强度曲线呈Ⅱ型者12例,Ⅲ型者1例;另一类表现为肿块型,5例(27.8%),时间-信号强度曲线呈Ⅰ型者1例,Ⅱ型者2例,Ⅲ型者2例。弥散加权成像发现病灶15例,检出率达83.3%,表面扩散系数(ADC)1.30×10-3mm2/s有10例。结论:乳腺导管原位癌MR图像上多表现为非肿块的段状分布及片状分布的异常强化,少数也可表现为肿块型改变,弥散加权成像在定性诊断上能起重要的辅助作用。     

Mucocele-like lesions of the breast: a benign cause for indeterminate or suspicious mammographic microcalcifications

Most earlier reports of mucocele-like lesions (MLL) of the breast have dealt with symptomatic cases in premenopausal women or lesions found incidentally in breast biopsies performed for other reasons. The diagnosis of this lesion has special challenges in the setting of mammographic screening for breast cancer because the imaging characteristics of MLL may mimic those of ductal carcinoma in situ (DCIS), while mucinous carcinoma enters the differential diagnosis on cytologic grounds. This report focuses on our experience with MLLs detected during screening mammography. Cases with MLL as the final histologic diagnosis in our database during January 1992-June 2000 are included. The results of clinical, imaging, cytologic, core biopsy, and histologic examination of these lesions are recorded. The relevant literature is reviewed. Twenty-six cases were found, with a mean patient age of 57.5 years. Microcalcifications were the dominant radiologic abnormality in 22 cases (84.6%). Imaging was considered suspicious or almost certainly malignant in 17 cases (65.4%). Cytology was classified as atypical or suspicious in 17 cases (70.9%). However, open biopsy showed mostly benign changes, including atypical ductal hyperplasia (ADH) in five cases (19.2%). In one case, ADH merged with a 3-4 mm focus of low-grade DCIS. This, the largest series focusing purely on screen-detected MLL, suggests that the combination of clinical, imaging, and cytologic features of screen-detected MLL are different from those of mucinous carcinoma, symptomatic MLL, or incidental MLL. Correlating the cytomorphology of mucinous lesions of the breast with their mammographic appearance may permit more precise preoperative diagnosis.     

High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer

We sought to prospectively assess the diagnostic performance of a high-resolution positron emission tomography (PET) scanner using mild breast compression (positron emission mammography [PEM]). Data were collected on concomitant medical conditions to assess potential confounding factors. At four centers, 94 consecutive women with known breast cancer or suspicious breast lesions received 18F-fluorodeoxyglucose (FDG) intravenously, followed by PEM scans. Readers were provided clinical histories and x-ray mammograms (when available). After excluding inevaluable cases and two cases of lymphoma, PEM readings were correlated with histopathology for 92 lesions in 77 women: 77 index lesions (42 malignant), 3 ipsilateral lesions (3 malignant), and 12 contralateral lesions (3 malignant). Of 48 cancers, 16 (33%) were clinically evident; 11 (23%) were ductal carcinoma in situ (DCIS), and 37 (77%) were invasive (30 ductal, 4 lobular, and 3 mixed; median size 21 mm). PEM depicted 10 of 11 (91%) DCIS and 33 of 37 (89%) invasive cancers. PEM was positive in 1 of 2 T1a tumors, 4 of 6 T1b tumors, 7 of 7 T1c tumors, and 4 of 4 cases where tumor size was not available (e.g., no surgical follow-up). PEM sensitivity for detecting cancer was 90%, specificity 86%, positive predictive value (PPV) 88%, negative predictive value (NPV) 88%, accuracy 88%, and area under the receiver-operating characteristic curve (Az) 0.918. In three patients, cancer foci were identified only on PEM, significantly changing patient management. Excluding eight diabetic subjects and eight subjects whose lesions were characterized as clearly benign with conventional imaging, PEM sensitivity was 91%, specificity 93%, PPV 95%, NPV 88%, accuracy 92%, and Az 0.949 when interpreted with mammographic and clinical findings. FDG PEM has high diagnostic accuracy for breast lesions, including DCIS.     

Preoperative MRI of pure intraductal breast carcinoma--a valuable adjunct to mammography in assessing cancer extent

The aim of the study was to evaluate the contribution of preoperative breast magnetic resonance imaging (MRM) as an adjunct to mammography in assessing extent of pure ductal carcinoma in situ (DCIS) and to relate magnetic resonance imaging (MRI) findings to histopathological features. A retrospective analysis was conducted of 86 histologically proven cases of pure DCIS of the breast. Two experienced radiologists with knowledge of clinical and histopathological findings at the time of the review evaluated mammographic and preoperative MRI results by consensus. Compared to histopathology, mammography or MRM alone underestimated DCIS extent in 18.6% and 31.4% of cases, respectively. When both imaging modalities were considered, DCIS extent was underestimated in 8% of cases. Combined use of mammography and MRM revealed good agreement with histopathology to assess DCIS extent (kappa=0.439; P<0.001). MR enhancement of DCIS was related to histologic size (P=0.011). Mammography is more accurate than MRM in assessing cancer extent of pure DCIS, but combined use of both imaging techniques leads to improved accuracy.     

乳腺血氧功能成像系统在乳腺疾病诊断中的应用

目的探讨乳腺血氧功能成像系统(血氧三算子)在乳腺疾病诊断中的应用价值。方法 2010年3月～9月对120例乳腺疾病进行血氧三算子、超声和乳腺钼靶检查(患者≤35岁不接受钼靶检查),3项检查至少有一项提示有手术指征,通过与术后病理对比,比较3种影像学诊断的准确性、敏感性、特异性、阳性预测值及阴性预测值。结果血氧三算子与超声、乳腺钼靶的准确率分别为93.3%(112/120)、87.5%(105/120)、82.4%(70/85);敏感性分别为93.5%(29/31)、74.2%(23/31)、61.5%(16/26);特异性分别为93.2%(83/89)、92.1%(82/89)、91.5%(54/59);阳性预测值分别为82.9%(29/35)、76.7%(23/30)、76.2%(16/21);阴性预测值为97.6%(83/85)、91.1%(82/90)、84.4%(54/64)。血氧三算子对乳腺病灶诊断的准确性、敏感性、阴性预测值优于乳腺钼靶(Z=2.212,P=0.027;Z=2.623,P=0.009;Z=2.735,P=0.006),但二者特异性和阳性预测值无统计学差异(Z=0.066,P=0.948;Z=0.395,P=0.693)。结论血氧三算子对乳腺病灶诊断具有较高的准确性、敏感性、阴性预测值,对乳腺癌的诊断有较大应用价值。